DEVELOPMENT OF AN ASO REAL-TIME PCR ASSAY FOR THE DETECTION OF THE DPYD rs67376798 VARIANT ASSOCIATED WITH FLUOROPYRIMIDINE METABOLISM
Main Article Content
Abstract
Background: The DPYD rs67376798 (c.2846A>T) variant reduces dihydropyrimidine dehydrogenase (DPD) activity, thereby increasing the risk of fluoropyrimidine-related toxicity due to drug accumulation.
Objective: To develop and preliminarily validate a SYBR Green-based allele-specific real-time PCR (ASO real-time PCR) assay for the detection of the DPYD rs67376798 variant.
Materials and Methods: This experimental study was conducted at the Biomedical Research and Laboratory Diagnostics Center, Pham Ngoc Thach University of Medicine, from February 2025 to June 2026. Allele-specific primers were designed with their 3′ ends targeting the variant site. Reference plasmids carrying the A (wild-type) and T (variant) alleles were constructed using cloning and site-directed mutagenesis, respectively, and subsequently confirmed by Sanger sequencing. Primer concentration and annealing temperature were optimized. Analytical specificity, amplification efficiency, and genotyping performance were evaluated using DNA samples from 23 human volunteers, with genotyping results compared against Sanger sequencing.
Results: Plasmid controls carrying allele A (wild type) and allele T (variant) were successfully constructed. The ASO primer system demonstrated high specificity, with no non-specific amplification products or primer-dimer formation observed. The optimal reaction conditions were determined to be a primer concentration of 0.1 µM and an annealing temperature of 66°C. Testing of 23 human DNA samples showed 100% concordance between the genotyping results (A/A) obtained using this protocol and those obtained by Sanger sequencing. However, further evaluation using samples with A/T and T/T genotypes is required to fully assess the protocol’s ability to discriminate between different genotypes and its overall reliability.
Conclusion: A SYBR Green-based ASO real-time PCR assay for detecting the DPYD rs67376798 variant was successfully developed. The preliminary findings support further evaluation of its analytical performance using samples representing different genotypes.
Keywords
DPYD, c.2846A>T, rs67376798, allele-specific real-time PCR
Article Details
References
2. Otero-Torres, S., Rodríguez-Mauriz, R., Fort-Casamartina, E., Clopés-Estela, A., Soler-Rotllant, F., Fontanals-Martínez, S., & Montero-Pérez, O. (2025). DPYD genotyping, fluoropyrimidine dosage and toxicity: an umbrella review of systematic reviews. Pharmaceuticals, 18(5), 727.
3. Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H., Swen, J. J., ... & Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clinical Pharmacology & Therapeutics, 103(2), 210-216.
4. gnomAD. (n.d.). gnomAD: Genome Aggregation Database. Truy cập Tháng 10 2026, from https://gnomad.broadinstitute.org/
5. Nguyễn, Ư. N., Nguyễn, Đ. K., & Nguyễn, H. N. T. (2026). Xây dựng quy trình giải trình tự Sanger chẩn đoán các biến thể di truyền trên gen dpyd liên quan đến tích lũy độc tính thuốc fluoropyrimidines. Tạp chí Y học Việt Nam, 558(2).